Articles From: Stellus Capital Investment Corporation to Report Fourth Quarter and Fiscal Year 2012 Financial Results and Hold Conference Call to Stephen F. Page Appointed to AeroVironment Board of Directors


2013/3/7
Stellus Capital Investment Corporation (NYSE: SCM) will release its financial results for the fourth quarter and year ended December 31, 2012 on Monday, March 11, 2013 after the market closes.
Sign-up for Stellus Capital Investment Corporation to Report Fourth Quarter and Fiscal Year 2012 Financial Results and Hold Conference Call investment picks
2013/4/18
NEWARK, Calif., April 18, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced the addition of the Byers Eye Institute at Stanford, located in Palo Alto, Calif., as a second site for the Company's Phase I/II clinical trial of its proprietary HuCNS-SC ® product candidate (purified human neural stem cells) in dry age-related macular degeneration (AMD). AMD is the leading cause of vision loss and blindness in people over 55 years of age, and approximately 30 million people worldwide are afflicted with the disease.
Sign-up for StemCells, Inc. Adds Byers Eye Institute at Stanford as Second Site for Phase I/II Clinical Trial in Dry Age-Related Macular Degeneration investment picks
2013/5/7
NEWARK, Calif., May 7, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) , a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the first quarter ended March 31, 2013 after the market close on Thursday, May 9.
Sign-up for StemCells, Inc. Announces Webcast to Discuss First Quarter 2013 Financial Results and Business Update investment picks
2013/4/9
NEWARK, Calif., April 9, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that it has closed a $10 million debt financing from Silicon Valley Bank (SVB). The loan funds will be used for general corporate purposes, and increase the Company's December 31, 2013 pro forma cash balance to $34.4 million.
Sign-up for StemCells, Inc. Closes $10 Million Debt Financing investment picks
2013/4/11
NEWARK, Calif., April 11, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that it has entered into an agreement with the California Institute for Regenerative Medicine (CIRM) under which CIRM will provide approximately $19.3 million to help fund preclinical development and IND-enabling activities of the Company's proprietary HuCNS-SC® product candidate (purified human neural stem cells) for Alzheimer's disease.
Sign-up for StemCells, Inc. Enters Agreement to Receive $19.3 Million From California Institute for Regenerative Medicine to Help Fund IND for Alzheimer's Disease investment picks
2013/3/20
NEWARK, Calif., March 20, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that it has acquired from NsGene A/S, a privately held Danish biotechnology company, a patent family claiming GFAP+ Nestin+ cells, including U.S. Patent Nos.
Sign-up for StemCells, Inc. Expands Patent Portfolio investment picks
2013/5/9
NEWARK, Calif., May 9, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) , a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today reported financial results for the first quarter ended March 31, 2013 and provided a business update.
Sign-up for StemCells, Inc. Reports First Quarter 2013 Financial Results and Provides Business Update investment picks
2013/3/19
NEWARK, Calif., March 19, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) , a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2012.
Sign-up for StemCells, Inc. Reports Fourth Quarter and Full Year 2012 Financial Results and Provides Business Update investment picks
2013/4/15
NEWARK, Calif., April 15, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that President and CEO Martin McGlynn will present an update on the Company's programs and operations at the 2013 Regen Med Investor Day to be held on Wednesday, April 17, 2013, at the Harmonie Club, 4 East 60 th Street, New York, NY.
Sign-up for StemCells, Inc. to Participate at 2013 Regen Med Investor Day in New York investment picks
2013/5/16
NEW YORK, May 16, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) , a clinical-stage biopharmaceutical company developing oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk, today announced the pricing of an underwritten public offering of 4,137,931 shares of its common stock at a public offering price of $14.50 per share.
Sign-up for Stemline Therapeutics Prices $60 Million Public Offering of Common Stock investment picks
2013/4/1
NEW YORK, April 1, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) (the "Company"), a clinical-stage biopharmaceutical company developing oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk, reported today its year-end 2012 financial results.
Sign-up for Stemline Therapeutics Reports Year-End 2012 Financial Results investment picks
2013/2/12
NEW YORK, Feb.
Sign-up for Stemline Therapeutics to Present at Leerink Swann and Company Global Healthcare Conference investment picks
2013/4/25
NEW YORK, April 25, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) , a clinical-stage biopharmaceutical company developing oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk, announced today that Ivan Bergstein, M.D., Chief Executive Officer, will present at the 12th Annual Needham Healthcare Conference on Wednesday, May 1, 2013 at 11:20 am ET.
Sign-up for Stemline Therapeutics to Present at the 12th Annual Needham Healthcare Conference on May 1, 2013 investment picks
2013/3/12
NEW YORK, March 12, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) , a clinical-stage biopharmaceutical company developing oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk, announced today that Ivan Bergstein, M.D., Chief Executive Officer, will present at the 25 th Annual Roth Conference on Wednesday, March 20th, 2013 at 8:00AM PT.
Sign-up for Stemline Therapeutics to Present at the 25th Annual Roth Conference on March 20, 2013 investment picks
2013/1/31
NEW YORK, Jan.
Sign-up for Stemline Therapeutics, Inc. Announces Closing of Initial Public Offering investment picks
2013/1/29
NEW YORK, Jan.
Sign-up for Stemline Therapeutics, Inc. Announces Exercise of Over-Allotment Option investment picks
2013/4/8
NEW YORK, April 8, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) today announced that an ongoing collaboration with the Dana-Farber Cancer Institute featuring SL-401, currently in late stage clinical development for hematological malignancies including blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML), has shown activity in an additional hematologic malignancy, multiple myeloma (MM), in preclinical models.
Sign-up for Stemline Therapeutics, Inc. Announces Presentation of SL-401 Preclinical Efficacy in Multiple Myeloma at the 14th International Myeloma Workshop in Kyoto, Japan investment picks
2013/2/7
NEW YORK, Feb.
Sign-up for Stemline Therapeutics, Inc. to Present at BIO CEO & Investor Conference on February 11th investment picks
2013/3/18
Step-out Exploration Results Enhance Prospects for Another Discovery at Wa Gold Project Canada NewsWire ASX Code -AZM TSX Code- AZR TORONTO , March 18, 2013 /CNW/ - Highlights: 4m @ 3.38g/t Au from 28m (JORC016) intersected 150m northwest of main Josephine North workings First-pass drill test of 'blind' Yiziri geochemical target returns 4m @ 1.05g/t Au from 60m (BNRD031) - 3km north of the Bepkong deposit RC drilling at Basabli returns good intercepts.
Sign-up for Step-out Exploration Results Enhance Prospects for Another Discovery at Wa Gold Project investment picks
2013/4/30
NORTHFIELD, Ill.
Sign-up for Stepan Announces Agreement To Acquire North American Polyester Resins Business From Bayer investment picks
2013/4/23
NORTHFIELD, Ill.
Sign-up for Stepan Announces First Quarter Earnings Conference Call And Webcast investment picks
2013/2/21
NORTHFIELD, Ill.
Sign-up for Stepan Approves Share Repurchase Authorization investment picks
2013/2/19
NORTHFIELD, Ill.
Sign-up for Stepan Declares Quarterly Dividend investment picks
2013/5/1
NORTHFIELD, Ill.
Sign-up for Stepan Declares Quarterly Dividend investment picks
2013/2/19
Fourth Quarter Net Income Up 17 Percent Full Year Net Income Up 10 Percent NORTHFIELD, Ill.
Sign-up for Stepan Reports Fifth Consecutive Year Of Record Earnings investment picks
2013/4/30
NORTHFIELD, Ill.
Sign-up for Stepan Reports First Quarter Results investment picks
2013/4/26
AeroVironment, Inc. (NASDAQ:AVAV) today announced that Stephen F.
Sign-up for Stephen F. Page Appointed to AeroVironment Board of Directors investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Stellus Capital Investment Corporation to Report Fourth Quarter and Fiscal Year 2012 Financial Results and Hold Conference Call to Stephen F. Page Appointed to AeroVironment Board of Directors
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity